Kinnate Biopharma (KNTE) Insider Trading & Ownership → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free KNTE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability Kinnate Biopharma (NASDAQ:KNTE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage41.70%Number OfInsiders Buying(Last 3 Years)4Amount OfInsider Buying(Last 3 Years)$11.31 MNumber OfInsiders Selling(Last 3 Years)0 Get KNTE Insider Trade Alerts Want to know when executives and insiders are buying or selling Kinnate Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address KNTE Insider Buying and Selling by Quarter Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. Kinnate Biopharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/8/2023James B TananbaumDirectorBuy1,780,000$2.80$4,984,000.00 5/4/2023Orbimed Advisors LlcDirectorBuy479,909$2.75$1,319,749.75 5/1/2023Carl L GordonDirectorBuy716,157$2.62$1,876,331.34 4/28/2023Carl L GordonDirectorBuy350,749$2.55$894,409.95 3/14/2022Richard Thomas WilliamsInsiderBuy25,000$8.37$209,250.00 3/11/2022Richard Thomas WilliamsInsiderBuy15,000$8.64$129,600.00 2/14/2022Carl L GordonDirectorBuy30,700$9.95$305,465.00 2/11/2022Carl L GordonDirectorBuy156,000$10.22$1,594,320.00 (Data available from 1/1/2013 forward) KNTE Insider Trading Activity - Frequently Asked Questions Who is on Kinnate Biopharma's Insider Roster? The list of insiders at Kinnate Biopharma includes Carl L Gordon, James B Tananbaum, Orbimed Advisors Llc, and Richard Thomas Williams. Learn more on insiders at KNTE. What percentage of Kinnate Biopharma stock is owned by insiders? 41.70% of Kinnate Biopharma stock is owned by insiders. Learn more on KNTE's insider holdings. Which Kinnate Biopharma insiders have been buying company stock? The following insiders have purchased KNTE shares in the last 24 months: Carl L Gordon ($2,770,741.29), James B Tananbaum ($4,984,000.00), and Orbimed Advisors Llc ($1,319,749.75). How much insider buying is happening at Kinnate Biopharma? Insiders have purchased a total of 3,326,815 KNTE shares in the last 24 months for a total of $9,074,491.04 bought. More Insider Trading Tools from MarketBeat Related Companies: NGM Biopharmaceuticals Insider Selling FibroGen Insider Selling Ocuphire Pharma Insider Selling LianBio Insider Selling Inovio Pharmaceuticals Insider Selling Avid Bioservices Insider Selling Sagimet Biosciences Insider Selling Vaxart Insider Selling Amylyx Pharmaceuticals Insider Selling Omega Therapeutics Insider Selling Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: 3 Penny Stocks That Insiders Are BuyingThe 3 Hottest Insiders Buys This Month 3 Companies Buying Back Cheap Stock LatelyPagaya Technologies: An AI Fintech That Insiders Are BuyingThe 5 Stocks Most Sold By Insiders This Year This page (NASDAQ:KNTE) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingShocking: One AI startup's revenue could surge 4,735%Manward PressHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable Prosperity[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kinnate Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.